Lifelong administration of colchicine is the mainstay of treatment for familial Mediterranean fever (FMF), whereas canakinumab, a monoclonal antibody that blocks the effects of interleukin (IL)-1β, can be used in case of colchicine resistance or its poor tolerability.
No takes yet. Share an insight, caveat, or question.
Barsuk et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: